Fusion protein of Exendin-4 tandem polypeptide and human serum albumin, preparation and application thereof

A technology of human serum albumin and fusion protein, which is applied in the field of genetically engineered protein drugs, can solve the problems of prolonging the action time and achieve the effect of not easy to lose, easy to enlarge, and mature fermentation process

Active Publication Date: 2009-09-09
浙江昂大久力生物制药有限公司
View PDF0 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, whether the fusion protein expressed by fusion of multiple Exendin-4 and human serum albumin genes can further prolong its action time in vivo has not been reported at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein of Exendin-4 tandem polypeptide and human serum albumin, preparation and application thereof
  • Fusion protein of Exendin-4 tandem polypeptide and human serum albumin, preparation and application thereof
  • Fusion protein of Exendin-4 tandem polypeptide and human serum albumin, preparation and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1: Construction of fusion protein expression plasmid

[0039] The E-L1-E-L2 gene was synthesized by Shanghai Bioengineering Technology Service Company and cloned in the pBluescript SK plasmid, where E is Exendin-4, L1 is [Gly-Gly-Gly-Gly-Ser]2, and L2 is Gly-Gly -Gly-Gly-Ser. The sequence is as follows:

[0040] 5' CTC GAG AAA AGA CAT GGA GAG GGA ACC TTC ACC TCC GAC TTG TCC AAA CAA ATG

[0041] GAG GAG GAG GCC GTC CGT CTT TTC ATC GAG TGG CTG AAA AAT GGA GGA CCT TCC

[0042] TCC GGA GCC CCT CCT CCT TCC GGT GGT GGT GGA TCT GGT GGT GGT GGA TCT CAT GGT

[0043] GAA GGT ACT TTT ACT TCT GAT TTG TCT AAA CAA ATG GAA GAA GAA GCT GTT AGA TTG

[0044] TTT ATT GAA TGG TTG AAG AAC GGT GGT CCA TCT TCT GGT GCT CCA CCA CCA TCT GGT

[0045] GGT GGT GGA TCC 3'

[0046] There are XhoI restriction site and BamHI restriction site at its 5' end and 3' end respectively.

[0047]In order to secrete and express E-L1-E-L2 and HSA in the form of fusion protein in Pichia pa...

Embodiment 2

[0049] Embodiment 2: the expression of fusion protein

[0050] Referring to the Pichia expression kit, inoculate the positive single clone expressing the fusion protein engineered bacteria into 100ml BMGY culture medium, culture on a shaker at 30°C / 230rpm overnight to make OD 600 Reach 4-8. The bacteria were collected by centrifugation at 3000rpm / 2 minutes, the bacteria were resuspended in 50ml of BMMY culture medium, and cultured on a shaker at 30°C / 230rpm. Methanol was added every 24 hours to a final concentration of 0.7%, induced continuously for 3 days, centrifuged at 5000 rpm / 10 minutes, and the supernatant was harvested and stored at -30°C.

Embodiment 3

[0051] Embodiment 3: the purification of fusion protein

[0052] According to the Pichia fermented liquid obtained in Example 2, use double-distilled water to dilute to make its conductance equivalent to that of the affinity balance buffer, and adjust the pH to 6.0-7.0. Dilute the diluted fermented liquid with a 0.45 μm micropore Membrane filtration, then concentrated to a small volume using an ultrafiltration system with a molecular weight cut-off of 10,000; then at a flow rate of 8ml / min, use 20mM sodium phosphate buffer (pH7.0) as the mobile phase, pass through a Blue Sepharose 6 FastFlow column (GE health) to adsorb the fusion protein, and finally eluted with 20mM sodium phosphate and 2M sodium chloride (pH7.0) buffer, then collected the elution peak, and the detection wavelength was set at 215nm, where the target peak 1 was the expression containing the fusion protein product( figure 1 ).

[0053] Collect the target peak 1 sample, add 20mM sodium phosphate and 2M ammon...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a fusion protein of Exendin-4 tandem polypeptide and human serum albumin, a preparation method and application thereof. The fusion protein of the Exendin-4 tandem polypeptide and the human serum albumin is expressed by a genetic engineering method. The fusion protein shows long-acting controlling blood sugar activity in a body, solves the problem that the half life period of the Exendin-4 tandem polypeptide in the body is short and has the advantage of convenient preparation. The fusion protein can be used for preparing diabetes medicaments and weight-losing products.

Description

technical field [0001] The invention relates to a genetically engineered protein drug prepared by recombinant DNA technology, specifically expressing a fusion protein of Exendin-4 tandem polypeptide and human serum albumin from Pichia pastoris. This fusion protein can be used as the main component of diabetes medicine. Background technique [0002] Exendin-4 is a glucagon-like peptide-1 (GLP-1) analog [1] . Its synthetic analogue, Exenatide, has been developed by Lilly Company and was approved by the FDA in 2005. Its trade name is Byetta. This product is used to treat β-cell function, and insulin injection is not needed for the time being. Oral diabetes drugs can no longer fully control blood sugar. levels of diabetics [2] . Due to the short half-life of Exendin-4 and the fact that diabetics are on almost life-long medication, multiple chronic doses (twice a day) are required. [0003] Human serum albumin (Human Serum Albumin, HSA) is a very important natural protein in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/70C12N15/81A61K38/38A61K38/26A61K9/08A61P3/10A61P3/04
Inventor 黄建松詹金彪管其君秦健孔建龙盛灵通朱小娟陆乐徐小蓉王安行徐海达
Owner 浙江昂大久力生物制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap